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A 3500 year old papyrus from ancient Egypt provides a list of treatments for many diseases 
including “bite hair loss”; most likely alopecia areata (AA). The treatment of AA remained 
largely unchanged for over 1500 years. In 30 CE, Celsus described AA presenting as scalp 
alopecia in spots or the “windings of a snake”, and suggested treatment with caustic compounds 
and scarification. The first “modern” description of AA came in 1813, though treatment still 
largely employed caustic agents. From the mid-19th Century onwards, various hypotheses of AA 
development were put forward including; infectious microbes (1843), nerve defects (1858), 
physical trauma and psychological stress (1881), focal inflammation (1891), diseased teeth 
(1902), toxins (1912), and endocrine disorders (1913). The 1950s brought new treatment 
developments with the first use of corticosteroid compounds (1952), and the first suggestion that 
AA was an autoimmune disease (1958). Research progressively shifted towards identifying hair 
follicle specific autoantibodies (1995). The potential role of lymphocytes in AA was made 
implicit with immunohistological studies (1980s). However, studies confirming their functional 
role were not published until the development of rodent models (1990s). Genetic studies, 
particularly genome wide association studies, have now come to the forefront and open up a new 
era of AA investigation (2000s). Today, AA research is actively focused on genetics, the 
microbiome, dietary modulators, the role of atopy, immune cell types in AA pathogenesis, 
primary antigenic targets, mechanisms by which immune cells influence hair growth, and of 




The history of alopecia areata (AA) is at least 3500 years old (Table I). However, researchers 
active in AA investigation have seen the field advance most significantly over the last ~30 years. 
From an average of 15 publications on AA per year in the 1950s, ~25 per year in the 1970s, ~55 
in the 1990s, to ~170 per year in the 2010s, the annual count is still small, but growing 
exponentially (Fig 1a). Only having to read around 50 new AA publications each year made life 
easy as a naïve PhD student in the 1990s (KM), but also daunting in that so little was understood 
about the nature of the disease. Nevertheless, the knowledge to draw on was rather better than for 
the first collegiate scholars of AA who presented brief dissertations to the Universities of 
Frankfurt and Berlin in 1857 and 1862.1,2 A modern student of AA has rather more publications 
to contend with (DB), but also a relatively better framework of understanding. This review 





It has been suggested that AA is described in the ancient Vedas (5000-400 BCE) of Ayurvedic 
medicine,3 though it is difficult to confirm the chronological provenance. The first known 
historical record of AA that can be claimed with reasonable confidence is written in the “Ebers 
papyrus”. Found between the feet of an Egyptian mummy and believed to date to 1500 BCE,4 the 
papyrus is the most extensive record of ancient Egyptian medicine yet discovered. It is primarily 
a list of medical treatments for use in the afterlife (Fig 2). In different locations, there are brief 
listings for “Nssq” hair loss which is believed to refer to patchy AA.5,6 
 
The 35th chapter of Hippocrates’ book “On Diseases” (~400 BCE) fleetingly alludes to 
blemishes where the hair is “foxy” in areas (after the Greek αλώπηξ = alopex, fox’s disease, 
alopecia), probably referencing mange which is relatively common in foxes.7 While it is not 
entirely clear whether Hippocrates was describing AA or androgenetic alopecia, mange can 
present in distinct patches visually similar to AA. AA may also have been described in ancient 
Chinese texts, though again it is not clear. Emperor Huang Ti (2696-2595 BCE), is credited for 
writing twelve scrolls which were eventually compiled (between 300-400 BCE) into a medical 
text now known as: "the Yellow Emperor's Classic of Internal Medicine". The text suggests that 
scalp or body hair can fall out if dietary food is too pungent, too bitter, or too sweet.8 
 
The first fully recognizable descriptions of AA are attributed to Cornelius Celsus (25 BCE - 50 
CE), a Roman encyclopedist translator of medical work. Celsus was not himself a doctor and 
most likely his translations were derived from the works of Menekrates (359-336 BCE). In the 
4th chapter of his 6th book De Medicina (~30 CE), Celsus described “Alopekia”, bald spots 
(after the Greek αλωπεκíα = alopecia) which occurred in both the scalp and the beard; and 
“Ophiasis”, bald areas that spread like the windings of a snake (after the Greek φίδι = snake). 
The ophiasis Celsus characterizes is not entirely the same as ophiasis AA defined today. Rather, 
Celsus describes ophiasis AA commencing at the back of the scalp, and “without exceeding two 
fingers in breadth” extends itself by two points of prolongation towards the ears, and in some it 
progresses onto the forehead, until the “two heads unite”.9,10 
 
Italian physician Girolamo Mercuriale (1530-1606), wrote “De morbis cutaneis” in 1572; 
generally considered the first “modern” scientific tract on skin diseases. AA is discussed within 
the book very much as a reflection of the ancient Greek transcripts, with respect to AA and 
treatments for the condition (see below).11 There was very little change in the presentation and 
advice on AA treatment in medical texts for ~1500 years. The works of Hippocrates, Celsus, and 
Galen, as well as the interpretations of Persian scholars, were frequently cited in transcripts until 
the 18th Century (eg.12-14). 
 
The first “modern” description of AA is widely attributed to Thomas Bateman (1778-1821) and 
Robert Willan (1757-1812). Instead of classifying skin diseases based on symptoms, Willan 
developed a system based on the appearance of skin disorders. After his death, Bateman 
continued to develop the system and published “A Practical Synopsis of Cutaneous Diseases 
According to the Arrangement of Dr Willan” in 1813. Bateman describes the essential 
characteristics of AA in patches, and cites Celsus. He alludes to infectious AA in groups of 
children, but also defines AA that occurs in isolation.15 
 
Possibly the first visual description of AA is in the painting of “Saint Sebastian” (1480; Paris, 
Louvre) by Andrea Mantegna. The bowman in the painting may have alopecia barbae.16 The first 
dermatology atlas to show AA was published in 1817 entitled “the Delineations of Cutaneous 
Disease”.17 It contains an engraved, hand colored plate of a male with multiple patches of AA 
(Fig 3). The first photographic image of AA was published in 1868 in a clinical atlas of 
dermatology showing a young boy with extensive AA.18  
 
 
What’s in a name? 
 
AA has been given many different names throughout history.19 The first known term for AA 
written in the Ebers papyrus translates as bitten or “bite alopecia”;5,6 a reasonable description of 
patchy AA. As is often cited, the word “alopecia” was used by Hippocrates,20 while “areas” of 
alopecia were first described by Celsus.9 In early literature, AA was sometimes known as “area 
Celsi” or “alopecia Celsi” as an acknowledgement.21-24 Also possibly in reference to Celsus’ 
description, AA was occasionally referred to in early texts by colloquial names including “fox’s-
evil”.25 In medieval and renaissance texts, AA is often referred to simply as “alopecia”, though 
the word can be written in different ways including “allopitie”,12 “allopicia”,13 alopecy”,26 and 
“alopefia”,14 among other variants. 
 
A description of an alopecia patch was first provided by the German physician Johannes Jonston 
(1603-1675) in his book “Medicina Practica” (1664).27 He wrote on the “alopecia area”: “Area 
est capillorum area-tim defluvium”. Consequently, rather than using the name Jonston provided, 
AA was sometimes known as “Area Jonstoni” (Jonston’s alopecia). The phrase “alopecia 
areata” was first used by the French dermatologist François Boissier Sauvages de Lacroix in his 
book “Nosologia Methodica”,28 However, while the term was first published in 1763, it took 
some considerable time for AA to become the near universally accepted description that is used 
today.  
 
In the 19th Century, “porrigo decalvans” was the more common term used for AA. Often first 
attributed to Willan,29 the term comes from classical Latin; porrīgō, meaning scurf, or dandruff, 
and dēcalvāns, meaning baldness. As the name suggests, there was considerable confusion 
between AA and ringworm, a confusion that persisted into the 20th Century. Due to this 
conflation, at times AA was also labelled as “tinea decalvans”.30,31 Based on the claim that AA 
was due to an infectious agent, Gruby suggested the name “phytoalopecia”.32 Wilson first 
described AA as “accidental alopecia”.33 Later, he used the term “porrigo decalvans”,34 but 
“accidental alopecia” and “alopecia accidentalis” were used in several 19th Century 
publications. While the approach is not perfect,35, using “Google Ngrams viewer”,36 one can see 
use of the term “porrigo decalvans” declined, while “alopecia areata” gradually gained 
acceptance from the 1850s onwards (Fig 1b). 
 
Names for variants and subtypes of AA can also be found. “Cazenave’s vitiligo”, “Celsus’ 
vitiligo”, “vitiligo capitis”, and “achromatous porrigo” were terms used to describe vitiligo of 
the scalp in association with AA.37-39 Cazenave (1795-1877) suggested AA was a subtype of 
vitiligo and made a connection between inflammation, vitiligo and AA.40 He also indicated 
changes in hair color and blanching could occur and, along with Rayer, that hair regrowth in AA 
patches tends to be initially non-pigmented.41,42 In parallel, Bazin named AA with hair 
depigmentation “tinea achromasota”.43,44 Over time, “Cazenave’s vitiligo” was more loosely 
applied to describe white hair in AA.  
 
The term “alopecia ophiasis”, clearly derives from the original descriptions by Celsus. The first 
time in print for the term “alopecia barbae” is in a German-Latin dictionary from 1691.45 
However, it takes 175 years before it appears again.46 The term “alopecia circumscripta” was a 
term probably first used by Fuchs and logically describes the patchy nature of AA.39 The term 
“alopecia universalis” first appeared in publications from 1739,47 “alopecia totalis” from 1839,48 
and “patchy alopecia areata” as a specific definition appeared in 1895 (Fig 1c).49 Identification 
of diffuse AA “Alopecia areata diffusa” did not occur until the mid-20th Century.50  
 
Of course the above nomenclature is primarily English vernacular derived from Latin and Greek. 
In other countries, languages, and systems of medicine, AA was, and still is, sometimes 
identified by other names. In French medical literature “La Pelade” was a common term used 
until quite recently. More rarely, "teigne pelade" "pelade achromateuse", "pelade ophiasique" 
and "pelade décalvante” were used.7 For India, in Ayurveda principles of medicine, AA is called 
“Indralupta” and “Ruhya” for alopecia universalis.51 In early Chinese texts AA received various 
names including “ghost shaved hair”, a colloquial term that is sometimes still used.52 In Chinese 
traditional medicine today, AA is usually defined as “oily wind”, a name that can be traced back 
to 1617 and Chen Shigong’s book "Surgical Authentic".53  
 
 
Treatments for AA  
The Ebers papyrus advocates several treatments (Fig 2) including a fig, sebesten, yellow ochre, 
frankinsense, goose-fat, and sweet beer mixture, applied to the scalp.5,6 Various treatments were 
suggested by the ancient Egyptians, with two purportedly from Queen Cleopatra herself.25,54-56 
Ancient Greek physicians recommended a plethora of therapeutic approaches using chemicals, 
herbs, and physical interventions (Table II). Celsus specified scarifying bald patches with a 
scalpel; and that; “some are painting on caustics mixed with oil, and especially burnt papyrus; 
some turpentine-resin with fennel”.9 Pliny the elder (23–79 CE) suggested onion mixed with 
honey or vinegar for AA. Persian scholar Rhazes (865–925 CE) cites Antyllus (~150 CE) as 
recommending scarification, cupping, and leeches.  
 
In the Middle Ages AA was believed to be due to corruption of the blood by black bile. 
Consequently treatment focused on improving the blood in various ways. In 1127, Stephen of 
Antioch produced a Latin translation of “Liber regalis” (al-Kitab al-Maliki) the work of Persian 
physician Hali Abbas (982–994 CE). In the “Practica” the text recommends bloodletting, pills 
and purges for AA.12 During the Renaissance, physicians significantly expanded treatment 
options, often with a focus on herbal remedies (Table II). By the early 18th Century, Turner 
(1667–1741) variously recommended; rubbing with a coarse linen cloth, fig-leaves, and onions 
to make the skin “wax red”, leeches, scarification, or acupuncture, followed by labdanum resin, 
pigeons-dung, delphinium plant seeds, bay leaf oil, turpentine and wax. Indeed, anything “which 
may excite or stir up the heat” and attract “nourishment to the parts”.57  
 
In the 19th Century, later editions of Bateman’s book “on skin diseases” suggested treatment by 
shaving, using friction, and oil of Mace dissolved in alcohol or prepared with tar oil, bitumen, 
camphor, or turpentine.58 Wilson recommended cantharides and lavender oil,33 or iodine and 
antimony.16 Fox endorsed mercury ointment.31 By the early 20th Century, a wide range of 
treatments were used for AA and there was little consensus on what was effective.59-61 In France, 
where the view lingered that infectious agents caused AA, antiseptic treatments continued to be 
promoted (Fig 4a). 
 
Reviewing the therapeutic modalities through history, it is notable that from the ancient 
Egyptians onwards, often the primary objective was to encourage skin irritation using physical or 
chemical methods. Irritant treatments, such as dinitrochlorobenzene and anthralin,62,63 and 
contact sensitization treatments such as squaric acid and diphencyprone,64,65 are effective AA 
therapies still in use today. In contrast, the 1950s brought a significant change in direction 
towards immuno-suppressive agents. In 1952, Dillaha and Rothman first used cortisone acetate 
to treat AA.66,67 They were, however, unclear on the mode of action, attributing the effect to “a 
change in local chemical milieu through some such manner as influencing sebaceous gland 
function or keratinization”. Later, it was recognized that corticosteroids act on inflammatory 
cells.68 While there have been attempts to develop other immuno-suppressive agents for AA 
(eg.69,70), corticosteroids remain the first treatment approach in most clinics worldwide. New 
immuno-regulatory treatments, such as JAK inhibitors, are on the horizon;71 time will tell if they 
become a mainstream therapeutic approach.72 
 
 
Hypotheses for AA pathogenesis 
 
The first attempt to explain AA pathogenesis comes from Chao Yuanfang (581–618 CE), a 
Chinese physician of the Sui Dynasty era. In his text “Treatise on the Origin and Symptoms of 
Diseases”, for AA pathogenesis he states; “There are people who have been invaded by the evil 
wind spirits in their heads. If they have a deficiency, they will lose their hair, their muscles will 
die. The hair loss patch can be just as big as a coin, or like a finger (in shape). The hair loss is 
long-lasting and not itchy, so it is called a ghost’s lick”.73 Later in the Ming dynasty, Chen 
Shigong (1555–1636), in his text “Surgical Authentic” states that AA; “is a blood asthenia (lack 
of energy) and cannot support the skin with qi (vital energy) and nourish the skin, so the hair 
roots are empty and peel off into pieces. The skin will be smooth and shining, itchy like insects 
crowing. It is because of the Hot Wind attack when the body is more on the asthenia side”.53 
With the onset of modern medicine in the 19th Century, efforts were made to research the 
underlying causes of AA.  
 
 
AA caused by infectious agents 
 
Gruby first presented an infectious agent hypothesis to explain AA pathogenesis in 1843.32 He 
discovered a fungus “Microsporum audouini” around the hairs in his Porrigo decalvans patients. 
The parasitic hypothesis for AA superficially made sense; the hair loss lesion expanded in size as 
a local infection would. The characteristics of AA, displaying rapid hair loss in a patchy manner, 
was similar to that seen in patients with ringworm or syphilis. A secondary effect of AA is that it 
can affect nail development, also similar to observations for syphilis.60,61 Reports of AA 
“epidemics” in institutions such as schools and orphanages were reported,15,74-77 which further 
circumstantially supported a parasitic hypothesis. The infectious agent explanation of AA 
pathogenesis became widely accepted at the time and the idea that AA was contagious persisted 
into the 20th Century. In France, development of AA was a cause for exemption from military 
service (Fig 4b).78 
 
However, data gradually accumulated against an infectious agent hypothesis.79 Some 
dermatologists isolated different fungi.80,81 Thin identified bacteria associated with AA and 
promptly renamed the condition “bacterium decalvans”.82 Bazin and Stowers viewed AA as 
caused by “tinea tonsurans” infection.43,83 Other dermatologists failed to identify any infectious 
agents unique to AA,84 and attempts to transfer the disease by inoculation also failed.85 
Inevitably, the most likely explanation for Gruby’s observation was the ambiguity in diagnosis 
between AA and tinea capitis at the time. Indeed, Sabouraud later concluded that Gruby was in 
fact studying patients with ringworm.27,86 Gradually, dermatologists shifted their opinion against 
an infectious cause of AA.87,88  
 
Although the idea that an infectious agent directly causes AA has been laid to rest, there is still a 
possible role for pathogen superantigens in increasing the general activity of the immune system, 
or more specifically by activating AA via antigen epitope mimicking.89,90 
 
 
AA as an atrophic nerve disorder 
 
Due to the inability to convincingly identify an organism with an etiological relation to AA, the 
idea of nerves being involved in AA was put forward relatively early and rapidly gained 
followers. Cazenave appreciated the frequent association of AA and vitiligo which he believed to 
be of nervous origin.91 With a detailed investigation, von Bärensprung showed nerve atrophy in 
AA affected skin and associated this with trophic nerve paralysis.24 Supporters of the AA 
“trophoneurosis theory” (also called the trophoneurotic, neurotrophic, or neuropathic theory) 
claimed other evidence supported this, such as apparent changes in skin sensation in the affected 
areas and neuralgic symptoms appearing before or during AA onset.79 Collier reported a case of 
a boy who was struck over the left ear in a fight, causing intense neuralgia, followed by AA of 
the left parietal region.10 A string of reports and studies followed linking changes to nerves with 
AA development (eg.92). 
 
More direct evidence was put forward by Max Joseph. Joseph showed that focal alopecia could 
be induced by cutting the spinal ganglia of the second cervical nerve in the necks of cats. After 
several days, he observed patchy hair loss develop in the region of skin that the nerve supplied. 
When he examined the skin’s histology he identified hair follicle atrophy, while the sweat and 
sebaceous glands were unaffected.93,94 These studies were not universally accepted however,95 
and Aubrun concluded that the alopecia was merely a consequence of scratching.96 A more 
intriguing variation on the neuropathic theory was put forward by Jacquet. He suggested AA was 
initiated by nerve irritation caused by defective and diseased teeth.97 Jacquet's claim was 
apparently confirmed by others.98,99 AA was also suggested to be linked to eye strain.100,101 
 
In more recent times, it has been shown that there are changes in the structure and signaling 
systems of nerves in areas of AA.102,103 Increased cutaneous stimulation may indeed be needed 
for sensory perception in AA skin.104 While nerve atrophy has been discounted as a primary 
cause of AA, there may be links between AA lesions and nerve innervation in affected skin and 
possibly other tissues.105 
 
 
AA as a psychosomatic disorder 
 
Over time the primarily physiological, neuropathic theory of AA pathogenesis transformed into a 
predominantly psychosomatic theory. This idea was supported by the frequent clinical 
observations of emotional stress and psychological trauma in advance of AA onset. Kinney 
presented a case of AA a few days after a shock caused by lightning striking a tree near the 
patient.106 Subsequently, similar examples were reported in medical journals (eg.100). For the 
most part the publications were case reports, there were few attempts to analyze large patient 
cohorts until the 1950s. A well cited study from Sheffield reported that AA was preceded by 
mental stress in 23% of 114 cases.107 Several reviews and investigations were then published 
linking psychosomatic issues to AA.108-110 The stress theory of AA eventually gained the support 




AA induced by toxins 
 
In the early 20th Century, another hypothesis of AA induction was put forward based on toxins 
inducing hair loss.112 The sudden remission and relapse of AA and its action in multiple regions 
of skin simultaneously over the scalp and body circumstantially supported the idea.113 
Additionally, injection of thallium acetate was shown to induce AA-like hair loss.112,114,115 AA 
was reported resulting from injections of quinine dihydrochloride and urethane,116 or after 
exposure to ethyl gasoline.117 Toxin induced AA was believed to stem in part from nerve atrophy 
due to the toxin effects and/or atrophy of the parathyroid glands.118 The toxic theory of AA 
pathogenesis never gained widespread popularity. Of note however, isolated reports still suggest 
a possible link between chemical exposure and AA onset (eg.119). 
 
 
AA as an endocrine disorder 
 
With the start of the 20th Century AA was known to be associated with endocrine disorders, 
particularly of the thyroid. Sabouraud presented cases of AA in association with goiters,120 while 
others suggested AA improved after treatment for hypo- and hyperthyroidism.121,122 Sabouraud 
also reported changes in AA during pregnancy and menopause.123,124 Analysis of 230 AA 
patients by Walker and Rothman revealed examples of thyrotoxicosis and hair regrowth during 
pregnancy.125 However, despite these reports, the hypothesis that AA was due to an endocrine 
disorder gained relatively little traction. The increased risk for development of autoimmune 




AA as an inflammatory disorder 
 
The earliest mention of inflammation in relation to AA in “modern” medical literature came 
from Wilson (1840) who very briefly suggested that the local cause of AA was defective 
nutrition due to poor capillary supply, or inflammation.33 The first evidence for inflammatory 
cells in and around hair follicles was produced from a post-mortem histological analysis of scalp 
skin.127 Surprisingly, despite observing leucocytes, and publishing the first drawing of hair 
follicle histology with inflammation, the authors dismissed their remark and focused on nerve 
atrophy. Later, Robinson observed peri-vascular and peri-follicular “round cell” infiltration by 
histology, but did not attempt to explain it.79 Unna, while concluding that AA was due to an 
infectious agent, also described inflammation in AA.128  
 
In 1891, Italian dermatologist Sébastien Giovannini examined 20 cases of AA using serial 
histological cross sections to reconstruct AA affected skin.129 His publication paints a picture of 
AA that would be recognized today. The progressive focal inflammation of anagen hair follicles, 
invasion of the dermal papilla, hair bulb matrix and root sheaths, disruption of hair follicle 
integrity and cell apoptosis, the regression of hair follicles into catagen, and the subsequent loss 
of hair, are well described. He claimed that inflammation could be observed in areas of skin in 
advance of hair loss and that there is infiltration of leucocytes into the follicles in all cases. Most 
significantly, Giovanini drew the bold conclusion that AA was directly caused by inflammation.  
 
However, Giovannini’s work failed to generate much interest. Unna acknowledged the 
“valuable” work of Giovannini, but disputed his conclusions on the significance of inflammation. 
His rejection seems to be based on his own observations that “markedly atrophic follicles, with 
almost no cellular infiltration around the deep part of the follicle” can be found in AA.128 Only 
much later, studies essentially confirmed Giovannini’s work and renewed interest in the local 
immune cell infiltrate.130-133  
 
 
AA as an autoimmune disorder 
 
Little progress was made in understanding AA pathogenesis until the late 1950s. Stephen 
Rothman was the first (known) person who referred to the possibility of autoimmunity in AA 
during the discussion of a presentation made in 1958.134 Rothman speculated that AA may be; 
“due to a displacement of melanin from melanocytes and to a subsequent allergic reaction with 
the formation of antimelanin antibodies. If this is so, cortisone and its derivatives may act as anti-
allergic and anti-inflammatory agents”. This observation slowly gained momentum and it took 
some time before AA research refocused on autoimmunity.  
 
Attempts were made to identify autoantibodies in AA patients, though initially with little 
success.135-137 Later, however, studies confirmed the presence of autoantibodies to various tissues 
in AA patients. Anti-nuclear antibodies,138,139 thyroid autoantibodies,140-142 antibodies against 
smooth muscle,143 and gastric parietal cells were all found.141 Endeavors to detect autoantibodies 
against hair follicle antigens initially failed.144-146 Eventually, reports were published 
demonstrating hair follicle specific autoantibodies present in AA affected patients and animals 
with AA.147-150 This was a significant step in that the studies were the first to confirm the 
immune system could mount a specific autoimmune response against hair follicle antigens.151  
 
 
The realization of a role for T lymphocytes in AA 
 
While the initial focus of autoimmune research in AA was on autoantibodies, it soon became 
apparent that a T cell mediated mechanism of AA pathogenesis was more likely. Little or no 
consistency in the targets for AA autoantibodies could be identified. Further, injection of AA 
patient serum into human scalp skin grafts on nude mice had no impact on hair growth.152 As the 
importance of autoantibodies in AA pathogenesis seemed to be limited, the focus of research 
(re)turned towards cellular inflammation. However, autoantibodies may yet have a significant 
role to play in directing research towards particular antigen epitopes.153,154  
 
It was suggested that hair follicles may have “immune privilege” and that its breakdown leads to 
AA.155,156 Paus and colleagues presented a hypothesis of AA pathogenesis based on autoreactive 
CD8+ cells targeting and disrupting hair follicles.157 They suggested microtrauma induced a 
localized “immune privilege collapse” in hair follicles which elicited a cytotoxic lymphocyte 
attack.158 While the proposal largely ignored conventional explanations for cell mediated 
autoimmune disease development (and still does), the hypothesis gained traction. Independently, 
McDonagh and Messenger also outlined a scenario in which hair follicles are attacked by 
lymphocytes 159. Consequently, there was considerable debate as to the role of lymphocytes in 
AA at the first few workshops on AA, organized by the National Alopecia Areata Foundation.160 
 
 
Animal models for alopecia areata 
 
As momentum began to build behind the idea that T cells could drive AA, new research tools 
were being developed; namely, rodent models of AA. Gilhar and colleagues began to manipulate 
AA skin grafted to nude mice, and later SCID mice, to show hair regrowth was possible in the 
absence of inflammation,161,162 to show autoantibodies were not pathogenic,152 to investigate the 
role of interferon-γ in AA,163 and ultimately to show that melanogenesis related peptide 
stimulated lymphocytes could induce AA in scalp skin.164,165 This was the first functional 
evidence that AA could be induced by transferring T cells into scalp skin and that hair follicle 
autoantigens could be involved in activating inflammatory cells.  
 
In the early 1990s, two models exhibiting spontaneous AA development were characterized; the 
“Dundee Experimental Bald Rat” (DEBR)166,167 and the C3H/HeJ mouse.168 With the DEBR 
model, antibodies were used to deplete CD8+ cells,169 and later CD4+ cells,170 to show that hair 
regrowth was possible with the removal of either cell population. The rat model was also used to 
investigate treatments for AA.171-173 Unfortunately, due to poor fecundity the DEBR colony died 
out in 2015, but the model served its purpose and provided evidence in support of a cell mediated 
AA disease mechanism. 
 
After developing the spontaneous C3H/HeJ mouse model into a skin graft induced model,174 a 
series of studies were conducted looking at immune cell infiltration in advance of hair loss,175 
examining treatments and modes of action,176,177 demonstrating that blockade of skin homing T 
cells using antibodies enabled hair regrowth,178 and beginning some, albeit limited, studies to 
investigate factors that may modulate susceptibility to AA.179-181 Over the past ~30 years, rodent 




Alopecia areata research in the modern age 
 
As we enter the next millennia, genetic studies, particularly genome wide association studies, 
have now come to the forefront and open up a new era of investigation.183 Our understanding of 
AA pathogenesis has advanced significantly, though it still has many gaps. Today, AA research 
is active in genetics,184,185 the microbiome, the role of the environment, the role of atopy,186 
immune cell types in AA pathogenesis,187 primary antigenic targets,153 mechanisms by which 
immune cells influence hair follicles, and of course the development of new treatments based on 
these discoveries. This increased AA research activity (Fig 1), from a larger number of 
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Figures 
 
Fig 1. Changes in AA description in medical texts over time. (a) A progressive increase in the 
number of AA related manuscripts published annually in peer reviewed journals by year to 2019. 
(b) Relative frequency of different names for AA in books over time using Google ngrams 




Fig 2. AA treatments in the Ebers papyrus. A section of the Ebers papyrus listing 6 treatments 
for alopecia areata (Eb 771-776). The first two lines state: “To make the hair grow for spotted 
baldness; burnt quills of hedgehog with oil, the head is anointed for four days” (Eb 771). Other 
AA treatments suggest rubbing a mixture of red ochre and beer into the scalp after scarification 
(Eb 772) and application of burnt flax plant mixed in oil with wasps’ “dung” (Eb 774) (Printed 
with permission, University of Leipzig, Germany). 
 
Fig 3. Engraved, hand colored plate of a male with multiple patches of AA. From: Bateman 
T, Willan R. Delineations of cutaneous diseases: exhibiting the characteristic appearances of the 
principal genera and species comprised in the classification of the late Dr. Willan and completing 
the series of engravings begun by that author. Longman, Hurst, Rees, Orme, and Brown; 1817 






Fig 4. AA in France in the early 1900s. (a) French advertisement for an “antiseptic” treatment 
for AA (la pelade) by Prof. Donnet in 1901, available from his pharmacy at 114 Rue 
Montmartre, Paris (KM, personal collection). As part of a multi-step treatment system, antiseptic 
lotion was applied to the scalp twice per day and L’eau Donnet was applied to alopecia spots 
three or four times per day with a small brush. The cost for a large bottle (~0.5 liters) was 8Fr; 1-
2 days average wage in French cities at the time.188 (b) A satirical cartoon of a soldier with AA 




Table I. A timeline of key developments in AA history 
Year Description References 
~1500 BCE The Ebers papyrus is written by an unknown scribe; the first 
known historical record of AA as “bite alopecia”. 
5,6 
~30 CE Cornelius Celsus, in De Medicina, describes “Alopekia”, bald areas 
which occurred in both the scalp and the beard; and “Ophiasis”, 
bald areas that spread like the windings of a snake. 
9,10 
~600 CE Chao Yuanfang, in his script Treatise on the Origin and Symptoms 
of Diseases, presents the first attempt to explain AA pathogenesis 
as an invasion by the evil wind spirits. 
73 
~980 CE Hali Abbas (Ali Abbas al-Majusi), in his script “Liber regalis” (al-
Kitab al-Maliki), categorizes AA as a form of leprosy and likens 
the nature of AA to snakes casting their skin.  
7,189 
~1170 The belief that AA is a form of leprosy persists and it is described 
as the “fox disease” by Roger Frugard. 
190 
1664 Johannes Jonston, in his text Medicina Practica, first uses the term 
“alopecia area”.  
27 
1763 François Boissier Sauvages de Lacroix, in his book Nosologia 
Methodica, first uses the phrase “alopecia areata”. 
28 
1813 Thomas Bateman, in his text A Practical Synopsis of Cutaneous 
Diseases According to the Arrangement of Dr Willan, publishes the 
first classification system based on the appearance of skin 
disorders. He describes the essential characteristics of AA in 
patches and cites Celsus. 
15 
1817 The first clinical visual representation of AA is published in The 
Delineations of Cutaneous Disease medical atlas. 
17 
1841 Erasmus Wilson, in one of four Lectures on diseases of the skin, 
makes the first recorded mention of inflammation in relation to AA, 
along with defective nutrition due to poor capillary supply. 
33 
1843 David Gruby publishes the first investigation demonstrating 
presence of “Microsporum audouini” around the hairs in AA 
patients and outlines the infectious agent hypothesis to explain AA 
pathogenesis. 
32 
1847 Pierre Louis Alphée Cazenave, publishes the first description of an 
association between AA and vitiligo; at the time thought to be of 
nervous origin. 
91 
1858 Felix von Bärensprung publishes the an investigation 
demonstrating nerve atrophy in AA affected skin associated with 
trophic nerve paralysis and defines the “trophoneurosis theory” to 
explain AA pathogenesis. 
24 
1881 Collier and other colleagues publish case reports describing 
physical trauma causing AA onset. 
10,191 
1881 Kinney and other colleagues publish case reports describing 
emotional distress and psychological trauma causing AA onset. 
106,192 
1882 Duckworth and Harris describe inflammatory cells in and around 
AA affected hair follicles, but dismiss the observation. 
127 
1886 Max Joseph presents the first investigation with an animal model of 
AA suggesting that patchy hair loss could be induced by cutting the 
spinal ganglia of the second cervical nerve in the necks of cats. 
93,94 
1891 Sébastien Giovannini identifies focal inflammation in and around 
AA affected hair follicles and hypothesizes an inflammatory 
mechanism of AA development. 
129 
1902 Lucien Jacquet presents an explanation for the neuropathic theory 
of AA identifying nerve irritation caused by defective and diseased 
teeth.  
97 
1912 Adamson and colleagues develop a hypothesis of AA pathogenesis 
based on toxins inducing hair loss. 
112,114,115 
1913 Sabouraud and colleagues publish reports of AA association with 
endocrine gland disorders, particularly the thyroid. 
120-122 
1950 A clinical data study by Anderson identifies increased 
psychosomatic stress in relation to AA onset. 
107 
1958 Rothman, in discussion of a presentation on AA by van Scott, 
hypothesizes that autoantibodies may attack hair follicles causing 
hair loss.  
134 
1963 A large scale epidemiology study by Muller and Winkelmann 
reveals several clinical associations with AA. 
193 
1965 Ikeda classifies four subtypes of AA, including “atopic AA”. 194 
1971 Billingham and Silvers identify hair follicle “immune privilege” 
after observing that melanocyte allotransplants to anagen hair 
follicles avoided immune rejection. 
195 
1977 An association between HLA class I and AA is identified. 196,197 
1985 HLA class II antigen expression is identified in AA affected hair 
follicles. 
155 
1990 Oliver and colleagues present the DEBR rat model of spontaneous 
AA. 
166,167 
1992 Gilhar and colleagues show plasma/autoantibodies from AA 
patients have little or no impact on hair growth. 
152  
1993 Interferon- is shown to be important for AA development by 
Gilhar and colleagues. 
163,198 
1993 Paus, Messenger and colleagues outline theories of AA 
pathogenesis based on the breakdown of hair follicle immune 
privilege leading to T cell inflammation. 
157,159 
1994 Sundberg and colleagues present the C3H/HeJ mouse model of 
spontaneous AA. 
168 
1995 Safavi and colleagues identify the lifetime risk for AA development 
using data from a large scale cohort. 
199 
1995 Tobin and colleagues identify hair follicle specific autoantibodies 
in blood plasma from AA patients. 
147-149,200 
1996 McElwee and colleagues show depletion of CD4+ and CD8+ T cells 
can restore hair growth in the DEBR AA model. 
169,170 
1998 Gilhar and colleagues show AA can be promoted by injection of T 
cells. 
164  
1998 McElwee and colleagues show AA can be transferred by skin 
grafting in the AA mouse model. 
174 
1999 Olsen and colleagues publish standardized clinical assessment 
investigational guidelines for AA. 
201,202 
2000 Freyschmidt-Paul and colleagues show blockade of T cell 
migration can prevent AA using the AA mouse model. 
178 
2001 Gilhar and colleagues show AA can be promoted by injection of T 
cells activated by melanocyte derived epitopes. 
165 
2003 David Whiting establishes the histologic features of AA in scalp 
biopsy specimens taken from different patterns and stages of AA 
and defines different patterns of hair follicle dystrophy. 
203 
2008 Ito and colleagues show that abnormal upregulation of MICA 
expression in AA hair follicles leads to them being attacked by 
NKG2D+ cells. 
204 
2010 Kang and colleagues demonstrate changes in immune privilege 
markers can occur in hair follicles from AA affected patients in 
overtly unaffected scalp skin areas. 
205 
2010 Petukhova and colleagues publish genome wide association studies 
(GWAS) identifying multiple susceptibility loci related to both the 
adaptive and innate immunity in AA patients.  
206 
2014 Bertolini and colleagues identify a role for mast cells in AA 
pathogenesis. 
207 
2016 Wang and colleagues demonstrate enrichment in the autoreactive T 
cell population of AA patients for both melanocyte and 
keratinocyte derived epitopes. 
153 
2018 A potential role for miRNAs in AA pathogenesis is suggested. So 





Table II. A timeline of treatment development in AA history  
Year Treatment description References 
~1500 
BCE 
The Ebers papyrus recommends; burnt flax plant mixed in oil with 
wasps’ “dung”; a carob, alabaster, and honey mixture, made while 
chanting a prayer to the sun god; and various other treatments. 
5,6 
~20 BCE Queen Cleopatra, in De Ornatu, suggests grinding up the heads of 
flies and rubbing them on the affected skin. Alternatively, (as cited 
by Bonham in 1630) Cleopatra recommends shaving the scalp, 
rubbing it with a linen cloth, and anointing the area with a soda 
alkali compound. 
25,55,56 
~30 CE Celsus, in De Medicina, recommends; scarifying bald patches with 
a scalpel and that; “some are painting on caustics mixed with oil, 
and especially burnt papyrus; some turpentine-resin with fennel”. 
Shaving daily with a razor to remove the surface skin and exposing 
the hair roots while continuing the treatment. After the initial hair 
growth response occurs, Celsus suggests a maintenance treatment 
applying Indian ink. 
9 
~60 CE Pliny the elder recommends onion mixed with honey or vinegar. 208 
~70 CE Dioscurides suggests topical application of tar oil mixed with barley 
flour. 
208 
~150 CE Antyllus (as cited by Rhazes (Abu Bakr Muhammad ibn Zakariya 
al-Razi)) defines scarification, cupping, and leeches for AA. 
209 
~190 CE Galen indicates massaging the scalp, then rubbing onion onto the 
skin. Also, puncturing the affected skin area before applying a 
mixture of crushed onion mixed with honey. Alternatively, shaving 
the head, applying mustard plasters to trigger skin redness, 
massaging the skin and then applying tar, cedar oil, fig leaves, or 
onion. 
210 
~660 CE Paulus Aegineta specifies removing any remaining scalp hair with 
sodium nitrate, rubbing with a woollen cloth to make the skin red 
and then applying the burnt shells of sea urchins mixed with bears 
grease. 
209 
~1000 Alsaharavius (Abu al-Qasim Khalaf ibn al-‘Abbas al-Zahrawi al-
Ansari) directs purging and applying a compound of mustard seed, 
euphorbium, pellitory, nettle-seed, oil of sesame, or pitch. 
209 
~1100 Avenzoar (Ibn Zuhr) endorses purging, regulating the diet, and oil 
of nuts and cherva. 
209 
~1127 Stephen of Antioch, in his translation of Liber regalis (al-Kitab al-
Maliki) by Hali Abbas, reports bloodletting, pills and purges for 
treating AA. 
12 
~1150 Maimonides (Moses ben Maimon) suggests ground adder skin 
mixed with honey. 
211 
~1170 Roger Frugard advises “sweet and sticky” medicines, bloodletting, 
scarification, and cautery. 
190 
1363 Guy de Chauliac in his book Chirurgia magna, originally published 
in 1363, records several treatments for AA attributed to scholars 
from ancient Greece and the Middle East. One credited to 
Archigenes of Syria involved a mixture of juniper, myrrh, and 
wormwood bitters, mixed with wine and oil, fermented for five 
days, and applied to the scalp. 
212 
1558 Gessner, in his text Historia animalium, advises dung of mice or 
weasels applied to the head cures the “foxes evil”. Attributed to 
ancient Egyptian texts. 
54 
1564 Ferrier advocates compound of rametti tree vines, bilberry, pine 
bark, and white roses; and with an alternative combination of oil of 
myrrh, aloes wood (resin), bark, tamarisk, wine and white clover. 
213 
1657 Vigier praises laxative pills for AA, taken once a day and made 
from rhubarb, oriental senna, and marine cabbage. 
214 
1731 Turner variously puts forward rubbing with a coarse linen cloth, fig-
leaves, and onions to make the skin “wax red”, leeches, 
scarification, or acupuncture, followed by labdanum resin, pigeons-
dung, delphinium plant seeds, bay leaf oil, turpentine and wax. 
Indeed, anything “which may excite or stir up the heat” and attract 
“nourishment to the parts” for treating AA. 
57 
1836 Bateman proposes regular shaving, using friction, and oil of Mace 
dissolved in alcohol or prepared with tar oil, bitumen, camphor, or 
turpentine for AA. 
58 
1841 Wilson points to camphor, cantharides, and lavender oil. Or 
alternatively, iodine and antimony, for AA. 
33,215 
1864 Watson reports on the use of carbolic acid to treat AA topically, as 
well as iron and quinine supplements orally. 
216 
1873 Fox endorses mercury ointment and cantharides for AA. 31 
1882 Thin presents case reports on the use of sulphur ointment for AA. 217 
1930s Chrysarobin, croton oil, formaldehyde and numerous other acidic 
and caustic chemicals are recommended for blistering the skin as a 
treatment for AA by various practitioners. 
59-61 
1952 Wilson successfully treats AA patients with adrenocorticotropic 
hormone (ACTH). 
218 
1952 Dillaha and Rothman first use oral systemic cortisone acetate to 
successfully treat AA. The mechanism of efficacy is unknown. 
66,67 
1955 Rony and Cohen first use local intradermal injections of 
hydrocortisone to successfully treat AA. The mechanism of efficacy 
is unknown. They also use topical fluoroeortisone acetate ointment, 
but without success.  
219 
1958 Kalkoff  and  Macher  confirm  that  the  local  injection  of  
hydrocortisone causes the peribulbar inflammatory cell infiltrate  to  
disappear in AA. 
220 
1977 Dinitrochlorobenzene (DNCB) is first used to treat AA by Frentz, 
Happle, and colleagues. 
62,221 
1978 Braun-Falco and colleagues use UVA light and psoralen (PUVA) to 
treat AA. 
222 
1979 Braun-Falco and colleagues treat AA by anthralin-induced 
dermatitis. 
63 
1980 Happle and colleagues successfully use squaric acid dibutylester 
(SADBE) to treat AA. 
64 
1981 Weiss and colleagues use minoxidil to treat AA. 223,224 
1983 Happle and colleagues first use diphencyprone (DCP) to treat AA. 225 
1986 Systemic cyclosporin is used successfully for the treatment of AA. 226-229 
1997 Topical FK506 (tacrolimus) is shown to be a promising treatment 
for AA in the rat model, however, in human studies this has not 
been the case. 
173,177 
2004 TNFα inhibitors, etanercept, infliximab, and adalimumab are 230-232 
suggested not to be effective treatments for AA and may even 
exacerbate the condition. 
2005 Heffernan and colleagues use alefacept to treat AA. 233 
2006 Kaelin and colleagues treat AA with efalizumab. 234 
2006 Joly uses methotrexate alone and in combination with 
corticosteroids to treat AA. 
235,236 
2013 Gilhar and colleagues suggest a potassium channel Kv1.3 blocker, 
PAP-1, could be a promising immunotherapy for AA.  
237 
2014 Clynes, Christiano and colleagues indicate JAK inhibitors, 
including baricitnib, tofacitinib and ruxolitinub, are promising 
treatments for AA. 
238-240 
 
